Elicio Therapeutics
ELTX
47 hedge funds and large institutions have $28.2M invested in Elicio Therapeutics in 2026 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 13 increasing their positions, 6 reducing their positions, and 7 closing their positions.
314% more call options, than puts
Call options by funds: $4.81M | Put options by funds: $1.16M
171% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 7
117% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 6
70% more capital invested
Capital invested by funds: $16.6M → $28.2M (+$11.7M)
27% more funds holding
Funds holding: 37 → 47 (+10)
2.46% more ownership
Funds ownership: 11.89% → 14.35% (+2.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.02M |
| 2 |
Renaissance Technologies
New York
|
+$903K |
| 3 |
Millennium Management
New York
|
+$896K |
| 4 |
Goldman Sachs
New York
|
+$558K |
| 5 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$290K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$412K |
| 2 |
Squarepoint
New York
|
-$133K |
| 3 |
OQS
Occudo Quantitative Strategies
Fort Lauderdale,
Florida
|
-$126K |
| 4 |
OAC
OMERS Administration Corp
Toronto,
Ontario, Canada
|
-$124K |
| 5 |
JFG
Jefferies Financial Group
New York
|
-$95.1K |
ELTX Hedge Fund Activity: Q1 2026 in Review
47 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Elicio Therapeutics (ELTX) for Q1 2026, worth a combined $28.2M — up 70% from $16.6M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ELTX positions and 7 closed out — a net gain of 12 holders — while 13 added to existing stakes and 6 trimmed.
The largest buyer was Balyasny Asset Management, adding an estimated $1.02M. The largest seller was Marshall Wace, cutting an estimated $412K.
- 47 institutional investors held Elicio Therapeutics (ELTX) as of Q1 2026, up from 37 in Q4 2025.
- Funds reported $28.2M of Elicio Therapeutics stock for Q1 2026, up 70% quarter-over-quarter.
- 19 funds opened new Elicio Therapeutics positions in Q1 2026 and 7 closed out, a net change of +12 holders.
- The largest Elicio Therapeutics buyer in Q1 2026 was Balyasny Asset Management, an estimated $1.02M added.
- The largest Elicio Therapeutics seller in Q1 2026 was Marshall Wace, an estimated $412K sold.
Based on aggregated 13F filings for Q1 2026.